Genomic Health Says Strong Oncotype DX Sales Help Boost Q3 Revenue 124 Percent | GenomeWeb
NEW YORK (GenomeWeb News) - Genomic Health yesterday said third-quarter revenues bolted 124 percent, R&D spending surged 75 percent, and net loss fell by 11 percent.
 
Total receipts for the three months ended Sept. 30 increased to $15.9 million from $7.1 million year over year.
 
Product revenues from Oncotype Dx jumped 129 percent to $15.8 million from $6.9 million, while contract revenue slid 40 percent to $120,000.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.